Loading
companiesCompany
Chipscreen Biosciences
Chipscreen discovered chidamide (tucidinostat), the first original epigenetic cancer drug from China, approved in 2014 and later in Japan.
Also called: 微芯生物
Overview
Chidamide (Epidaza) approved 2014 for T-cell lymphoma and 2019 for breast cancer; licensed to HUYA Bioscience (HBI-8000) with Japanese approval 2021 and to Meiji Seika; chiglitazar for diabetes. Founded by Xianping Lu, a returnee from US biotech, before China's regulatory reforms made originator research routine.
Headquarters
Shenzhen, CN
Scorecard
All companies#90of 1244 companies, score 53
- approved products +6
- phase 3 +3
- targets +10
- modalities +2
- regions +2
- registry trials +30
1 approved, 1 in phase 3, 0 earlier, 5 targets, 242 registry studies. Formula on the scorecards page.
Type
Biotech · 688321.SS
Stage
Public
Website
Founded
2001
ApprovedSmall-molecule oral subtype-selective HDAC inhibitor
Tucidinostat (chidamide) · Epidaza
Chidamide, approved in 2014, was the first epigenetic cancer drug invented in China and the first oral drug of its kind anywhere, used for T-cell lymphoma and, with hormone therapy, for breast cancer.
Phase 3small molecule
Chiauranib is an experimental small-molecule drug from Chipscreen Biosciences in phase 3 trials for ovarian cancer, aimed at VEGF / VEGFR and KIT.
Similar pages
- TreatmentSintilimab
Shares A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients and the tag china.
fronts
drugs
Phase 3small molecule
ApprovedSmall-molecule oral subtype-selective HDAC inhibitor
Tucidinostat (chidamide) · Epidaza
companies
trials
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer PatientsChiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian CancerTucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype